礼来:FRα ADC 临床数据首秀,KRAS G12C 抑制剂联合 K 药一线治疗 NSCLC 数据公布...

Insight数据库
Jun 02, 2025

2025 年 ASCO 大会火热进行时,礼来在本次大会上带来几项在研药物的新数据,包括 Imlunestrant(口服选择性 ER 降解剂)、Olomorasib(KRAS G12C 抑制剂)、LY4170156(FRα ADC)以及阿贝西利(CDK4/6 抑制剂)。本文将挑选部分进行具体介绍,供读者参考。*由于文章篇幅有限,难以纳入所有重要研究结果。欢迎使用 Insight 数据库进行查阅(长按...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10